Outlook Therapeutics Inc (OTLK)

01:43 AM

Outlook Therapeutics (NASDAQ:OTLK) vs. Novavax (NASDAQ:NVAX) Head-To-Head Survey - Defense World

01:43 AM

May 15, 2025

Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News - GuruFocus

May 15, 2025

May 15, 2025

Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025

May 15, 2025

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

May 15, 2025

May 15, 2025

Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

May 15, 2025

May 15, 2025

Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025 - Stock Titan

May 15, 2025

May 14, 2025

Outlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on Wednesday - Defense World

May 14, 2025

May 06, 2025

Renaissance Technologies LLC Acquires New Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

May 06, 2025

May 02, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

May 02, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 28, 2025

Russell Investments Group Ltd. Boosts Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 28, 2025

Apr 27, 2025

INVESTOR ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Apr 27, 2025

Apr 19, 2025

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN

Apr 19, 2025

Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights - openPR.com

Apr 17, 2025

Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail

Apr 17, 2025

Apr 12, 2025

25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World

Apr 12, 2025

Apr 11, 2025

Outlook Therapeutics Approves Retention Incentive for CFO - MSN

Apr 11, 2025

Apr 10, 2025

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com

Apr 10, 2025

Apr 10, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada

Apr 10, 2025

Apr 09, 2025

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times

Apr 09, 2025

Apr 09, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com

Apr 09, 2025

Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus

Apr 08, 2025

Apr 08, 2025

OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener

Apr 08, 2025

Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com

Apr 08, 2025

Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq

Apr 08, 2025

Apr 08, 2025

Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan

Apr 08, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025

Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025

Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025

Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025

Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025

Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025

Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025

Mar 10, 2025

Sun Pharma to Acquire Checkpoint Therapeutics Inc for Up to $355 Million - outlookbusiness.com

Mar 10, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025